Asthma Pipeline Analysis Report 2026

Report Coverage

The Asthma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into asthma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for asthma. The asthma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The asthma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with asthma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to asthma.

Read more about this report - Request a Free Sample

Asthma Pipeline Outlook

Asthma is a chronic respiratory disease characterized by persistent airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction. It occurs when genetic susceptibility and environmental triggers, such as allergens, infections, pollutants, or exercise, activate immune responses, causing airway narrowing, mucus overproduction, and breathing difficulties, including wheezing, coughing, chest tightness, and shortness of breath.

Asthma treatment focuses on controlling airway inflammation, relieving bronchoconstriction, and preventing exacerbations. Management includes inhaled corticosteroids, bronchodilators, combination inhalers, leukotriene modifiers, biologic therapies for severe asthma, and personalized treatment strategies to improve lung function and reduce asthma attacks. In January 2023, the U.S. Food and Drug Administration (FDA) approved Airsupra (albuterol and budesonide) inhalation aerosol for adults with asthma. This combination therapy became the first inhaled corticosteroid and short-acting beta-agonist reliever approved in the United States, reducing severe asthma attacks while providing rapid bronchodilation and anti-inflammatory benefits.

Asthma Epidemiology

The growing global burden of asthma continues to drive innovation in the pipeline analysis, as rising disease prevalence highlights the need for more effective and targeted therapies. According to Sarya Swed et al. (2024), approximately 8.7% of the United States population is affected by asthma, while prevalence estimates have historically ranged from below 3% to above 20%. According to Tejas Menon Suri et al. (2024), more than 34 million people in India have asthma, accounting for nearly 13% of the global asthma burden. These epidemiological trends continue to accelerate drug development, clinical trials, and the advancement of novel asthma therapeutics worldwide.

Asthma – Pipeline Therapeutic Assessment

Asthma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, accounts for 38%, covers a major share of the total asthma clinical trials, driven by active efficacy and dose-optimization studies that strengthen the pipeline. Phase III follows with a 29%, reflecting late-stage clinical validation. Phase IV holds 20% with post-marketing evidence, while phase I contributes 13% with early safety assessments, supporting sustained therapeutic innovation and market growth.

Asthma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Asthma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides and polymers. The Asthma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for asthma. Janus kinase inhibitors are emerging as a promising drug class in the asthma drug pipeline, particularly for patients with uncontrolled asthma. For instance, frevecitinib (KN-002), an inhaled pan-Janus kinase inhibitor, is under Phase 2b evaluation. It is designed to deliver targeted lung therapy, reduce airway inflammation, and improve disease control while minimizing systemic exposure.

Asthma Clinical Trials – Key Players

The EMR report for the asthma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed asthma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in asthma clinical trials:

• Generate Biomedicines
• Enveda Therapeutics
• Apogee Therapeutics, Inc.
• Shanghai Mabgeek Biotech. Co. Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Teva Branded Pharmaceutical Products R&D LLC
• Novartis Pharmaceuticals
• Haisco Pharmaceutical Group Co., Ltd.
• GlaxoSmithKline
• AstraZeneca
• Connect Biopharm LLC

Asthma – Emerging Drugs Profile

Key Questions Answered in the Asthma Pipeline Insight Report

• Which companies/institutions are leading asthma drug development?
• Which company is leading the asthma pipeline development activities?
• What is the current asthma commercial assessment?
• What are the opportunities and challenges present in the asthma pipeline landscape?
• What is the efficacy and safety profile of asthma pipeline drugs?
• Which company is conducting major trials for asthma drugs?
• Which companies/institutions are involved in asthma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in asthma?

Reasons To Buy This Report

The asthma pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for asthma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into asthma collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Asthma Treatment Market

Asthma Epidemiology Forecast